NCT07056309View on ClinicalTrials.gov

A Study of Remternetug (LY3372993) in Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy
Interventions
DRUG

Remternetug (Test)

Administered SC

DRUG

Remternetug (Reference)

Administered SC

Trial Locations (3)

32117

Fortrea Clinical Research Unit, Daytona Beach

65802

QPS Missouri, Springfield

75247

Fortrea Clinical Research Unit, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY